We have previously demonstrated that the thiazole derivative 3-methylcyclopentylidene-[4-(4 0 -chlorophenyl)thiazol-2-yl] hydrazone (CPTH6) induces apoptosis and cell cycle arrest in human leukemia cells. The aim of this study was to evaluate whether CPTH6 is able to affect autophagy. By using several human tumor cell lines with different origins we demonstrated that CPTH6 treatment induced, in a dose-dependent manner, a significant increase in autophagic features, as imaged by electron microscopy, immunoblotting analysis of membrane-bound form of microtubule-associated protein 1 light chain 3 (LC3B-II) levels and by appearance of typical LC3B-II-associated autophagosomal puncta. To gain insights into the molecular mechanisms of elevated markers of autophagy induced by CPTH6 treatment, we silenced the expression of several proteins acting at different steps of autophagy. We found that the effect of CPTH6 on autophagy developed through a noncanonical mechanism that did not require beclin-1-dependent nucleation, but involved Atg-7-mediated elongation of autophagosomal membranes. Strikingly, a combined treatment of CPTH6 with late-stage autophagy inhibitors, such as chloroquine and bafilomycin A1, demonstrates that under basal condition CPTH6 reduces autophagosome turnover through an impairment of their degradation pathway, rather than enhancing autophagosome formation, as confirmed by immunofluorescence experiments. According to these results, CPTH6-induced enhancement of autophagy substrate p62 and NBR1 protein levels confirms a blockage of autophagic cargo degradation. In addition, CPTH6 inhibited autophagosome maturation and compounds having high structural similarities with CPTH6 produced similar effects on the autophagic pathway. Finally, the evidence that CPTH6 treatment decreased a-tubulin acetylation and failed to increase autophagic markers in cells in which acetyltransferase ATAT1 expression was silenced indicates a possible role of a-tubulin acetylation in CPTH6-induced alteration in autophagy. Overall, CPTH6 could be a valuable agent for the treatment of cancer and should be further studied as a possible antineoplastic agent. Autophagy has been predominantly characterized as a nonselective degradative pathway activated by starvation. In this context, it is a process known to provide metabolic sources to the cell under nutrient depletion or other stresses. However, it has become apparent that autophagy is not solely dedicated to nutrient management, and a nutrient-independent 'basal' autophagy has been defined.
We have previously demonstrated that the thiazole derivative 3-methylcyclopentylidene-[4-(4 0 -chlorophenyl)thiazol-2-yl] hydrazone (CPTH6) induces apoptosis and cell cycle arrest in human leukemia cells. The aim of this study was to evaluate whether CPTH6 is able to affect autophagy. By using several human tumor cell lines with different origins we demonstrated that CPTH6 treatment induced, in a dose-dependent manner, a significant increase in autophagic features, as imaged by electron microscopy, immunoblotting analysis of membrane-bound form of microtubule-associated protein 1 light chain 3 (LC3B-II) levels and by appearance of typical LC3B-II-associated autophagosomal puncta. To gain insights into the molecular mechanisms of elevated markers of autophagy induced by CPTH6 treatment, we silenced the expression of several proteins acting at different steps of autophagy. We found that the effect of CPTH6 on autophagy developed through a noncanonical mechanism that did not require beclin-1-dependent nucleation, but involved Atg-7-mediated elongation of autophagosomal membranes. Strikingly, a combined treatment of CPTH6 with late-stage autophagy inhibitors, such as chloroquine and bafilomycin A1, demonstrates that under basal condition CPTH6 reduces autophagosome turnover through an impairment of their degradation pathway, rather than enhancing autophagosome formation, as confirmed by immunofluorescence experiments. According to these results, CPTH6-induced enhancement of autophagy substrate p62 and NBR1 protein levels confirms a blockage of autophagic cargo degradation. In addition, CPTH6 inhibited autophagosome maturation and compounds having high structural similarities with CPTH6 produced similar effects on the autophagic pathway. Finally, the evidence that CPTH6 treatment decreased a-tubulin acetylation and failed to increase autophagic markers in cells in which acetyltransferase ATAT1 expression was silenced indicates a possible role of a-tubulin acetylation in CPTH6-induced alteration in autophagy. Overall, CPTH6 could be a valuable agent for the treatment of cancer and should be further studied as a possible antineoplastic agent. Autophagy has been predominantly characterized as a nonselective degradative pathway activated by starvation. In this context, it is a process known to provide metabolic sources to the cell under nutrient depletion or other stresses. However, it has become apparent that autophagy is not solely dedicated to nutrient management, and a nutrient-independent 'basal' autophagy has been defined. 1 It occurs at basal levels in most tissues and contributes to the routine turnover of cytoplasmic components, thus enforcing intracellular quality control. 2 Induction of autophagy may be a double-edged sword, as it is also a mechanism leading to cell death when destruction of cell cytoplasm components is activated in a long-lasting way. 3 Autophagy is triggered by various stimuli, is mediated by a number of proteins encoded by autophagy-related genes (Atgs) and is usually described as a cascade of events such as nucleation, elongation, maturation and fusion. A canonical mechanism of nucleation (de novo formation) of autophagosomal membranes depends on beclin-1, which interacts with adaptor protein p150 to stimulate activity of PI3-kinase VPS34. 4 The elongation requires Atg-12, Atg-3, Atg-5 and Atg-7, 5 whereas lysosome-associated membrane proteins 1 and 2 (LAMP-1 and LAMP-2) regulate the late step of the autophagic process.
Autophagic pathway can be inhibited by pharmacological inhibitors at different steps: PI3-kinase inhibitors block autophagosome formation; 6 microtubule-disrupting agents and endoplasmic reticulum stressors inhibit autophagosomelysosome fusion; 7, 8 and lysosomal proteases inhibitors and acidification modulators strongly reduce final degradation of autophagic cargo inside autolysosome. 9 Recently, the cross-talk between autophagy and apoptosis has been considered as a key factor in the development and treatment of cancer. 3 The two pathways share molecular regulators and, in some cases, are activated by the same stimulus. Despite the great deal of interest in the regulation of autophagy for therapeutic purposes, there are only few modulators of the autophagic pathway that have shown promising pharmacological value.
derived from thiazole, has been characterized for its ability to activate apoptotic program in human acute myeloid leukemia cell lines (AML). 13, 14 Here, by using either pharmacological or genetic means at the early or late stages of autophagy, we analyzed the effect of CPTH6 on autophagic pathway on a panel of human cancer cell lines.
Results
CPTH6 induces a block of basal autophagy. We previously demonstrated that tumor cell lines undergo apoptosis after CPTH6 treatment.
14 Because many lines of evidence suggest a link between apoptosis and autophagy, 15 in this paper we examined the effect of CPTH6 on autophagy in several tumor cell lines with different histotypes.
We first analyzed CPTH6-induced changes in the levels of autophagosomal marker microtubule-associated protein 1 light chain 3 (LC3B) in leukemia, melanoma, ovary and lung carcinoma cell lines, exposed to increasing concentrations of CPTH6 for 72 h ( Figure 1A ). Upon treatment with CPTH6, a significant increase in the amount of LC3B-II in a dose-dependent manner was observed, although to a different extent, in all cell lines.
Formation of punctate spots (puncta) with enhanced green fluorescence protein (EGFP)-LC3B reporter is a well-characterized marker to visualize autophagosomes and represents the accumulation of LC3B-II on autophagic vesicles. Thus, we analyzed autophagosome formation in H1299 cells stably expressing EGFP-LC3B protein treated with 100 mM CPTH6 from 6 to 72 h. As shown in Figures 1B and C, a diffuse cytoplasmic distribution of green fluorescence was observed in untreated cells, whereas a characteristic redistribution of EGFP-LC3B from a diffused staining to puncta was evident, already 6 h after treatment, in a timedependent manner. A dose-dependent effect was also observed in M14 cells (Supplementary Figure 1A, B) .
The formation of autophagosomes induced in H1299 cells by CPTH6 treatment was also examined with transmission electron microscopy (TEM). As reported in Figure 1D , the induction of autophagy was witnessed by vacuolization of the cytoplasm because of cytotoxic treatment, not observed in the control cells. Only few and immature autophagosomes, characterized by an electron density equivalent to the cytoplasm, coexisting with late vesicles (primary and secondary lysosomes) were observed after 24 h of CPTH6 treatment. Treated cells did not contain double-membrane autophagic vacuoles, and the membrane structures observed in the cytoplasm may be attempting to form phagophores, which should have led to the construction of autophagosomes.
The increase in LC3B-II levels induced by CPTH6 treatment could be related to either enhanced autophagosome formation, due to an increase in autophagic activity, or reduced turnover of autophagosomes, due to an impairment of the degradation pathway. [16] [17] [18] Only if autophagy is activated by CPTH6, late-stage autophagy inhibitors will be expected to further increase LC3B-II level and the number of autophagosomes. Therefore, to discriminate between the two possibilities, we utilized the early-stage autophagy inhibitor 3-methyladenine (3-MA) and the two late-stage inhibitors bafilomycin A1 and chloroquine. Autophagy inhibition by 3-MA completely blocked CPTH6 effect on LC3BI-II conversion and LC3B puncta formation observed in M14 (Figure 2a ) and U-937 cells (Supplementary Figure 1C) . In contrast, time course assessment of LC3B turnover demonstrated that bafilomycin A1 or chloroquine failed to further enhance LC3B-II level and LC3B puncta in cells treated with CPTH6 even at shorter time exposure (Figures 2a and b and Supplementary Figure 1E ). As expected, the autophagy-related features induced in U-937 cells by canonical stimuli, such as serum starvation, were suppressed by 3-MA (Supplementary Figure 1D ), whereas addition of bafilomycin A1 in M14 cells ( Figure 2a ) and in U-937 (Supplementary Figure 1D) resulted in a conspicuous increase in LC3B-II levels, concomitantly with an increased appearance of puncta EGFP-LC3B. As exposure to 3-MA represents a condition that can paradoxically induce autophagy by inhibiting class I PI3-kinase, 19 the effect of 3-MA on Akt/mTOR pathway has been investigated in both U-937 and H1299 cells. Western blot analysis demonstrated that phosphorylation of either Akt at Ser473 or mTOR was not affected by exposure to 3-MA (data not shown).
To monitor the effect of CPTH6 on cargo incorporation, which occurs concurrent with autophagosome maturation, we analyzed colocalization of LC3B protein with the adaptor protein p62. 20 As shown in Figures 2c and d , CPTH6 treatment of M14 cells stably expressing EGFP-LC3B induced a large increase in p62 bodies and LC3B puncta when compared with untreated cells. Many of these structures colocalize, and a similar pattern of p62 and LC3B localization was also observed in cells after starvation-induced autophagy (Figures 2c and d) . CPTH6 treatment also increased p62 protein level in other tumor cell lines (Figure 2f and Supplementary Figure 2A ). An increase in the level of NBR1, another protein selectively degraded during autophagy, was also observed (Figure 2f ). As expected, in U-937 cell lines, p62 was reduced by serum starvation (Figure 2e ).
As a cross-talk between proteasome-mediated degradation and autophagy has been found, 21 and p62 protein degradation may happen via proteasomal pathway, 22 we investigated if CPTH6 could act as a proteasome inhibitor. As shown in Figure 2g , increased p62 protein expression after CPTH6 treatment of U-937 cells was associated with modulation of neither ubiquitinated proteins, nor the expression of HIF-1a or phosphorylated IkBa, the two proteins whose degradation proceeds through proteasomal pathway. Moreover, the proteasome inhibitor, MG132, increased the expression of HIF-1a and the phosphorylated IkBa, as expected, whereas it did not affect p62 protein level. Similar results were observed in H1299 cells (Supplementary Figure 2B) . Thus, this indicates that in our experimental models, proteasome pathway is not involved in CPTH6-induced p62 protein accumulation. All together, these results suggest that the increased autophagic markers in CPTH6-treated cells under basal condition are unlikely due to enhanced autophagic flux, but rather by suppression of late maturation stage.
Atg-7, but not Beclin-1, is required for CPTH6-induced autophagic features. Subsequent experiments were performed to evaluate the impact of several proteins acting in different steps of autophagy on the ability of CPTH6 to modulate autophagic markers, such as p62 and LC3B-II. Specifically, the roles of beclin-1-dependent nucleation and Atg-7-mediated elongation steps of the autophagic cascade were investigated, together with the role of LAMP-2, a component of lysosomal membrane proteins, required for the proper fusion of autophagosome and lysosome. To this purpose, H1299 cells were stably transfected with short hairpin RNA (shRNA) targeting beclin-1 or transiently transfected with small interfering (siRNA) directed against Atg-7 or LAMP-2 ( Figure 3 ). As control, cells were transfected with control shRNA vector or scrambled siRNA. Western blot analyses confirmed the effective knockdown of each target expression (Figures 3a-c) , and demonstrated that CPTH6 did not affect the expression of beclin-1, Atg-7 and LAMP-2 proteins. Surprisingly, knockdown of beclin-1 failed to prevent the increase in LC3B-II and p62 levels and autophagosome formation triggered by CPTH6 (Figures 3a, d and e), whereas cells depleted of beclin-1 completely prevented starvation-induced autophagy (data not shown). On the contrary, silencing of Atg-7 completely blocked CPTH6 effect on autophagy, being the expression of p62 and LC3B-II and the formation of puncta superimposable to Collectively, these results suggest that CPTH6 triggered an unconventional autophagy that bypassed the beclin-1-dependent nucleation of autophagosomal precursors, and that Atg-7 mediates accelerated autophagic flux resulting from CPTH6 exposure.
Autophagosomes must fuse to lysosomes to degrade their contents. The inability of CPTH6-treated cells to degrade protein aggregates, despite an apparent induction of autophagosomes, prompted us to ask whether CPTH6 interferes with autophagosome-lysosome fusion. To this end, we examined LAMP-2-dependent fusion of autophagosomes with lysosomes to form autolysosomes by tracking the late endosome/lysosome marker LAMP-2, detecting its colocalization with the autophagosomal marker LC3B. As shown in Figure 4a , both serum starvation and CPTH6 treatment induced EGFP-LC3 puncta in M14 cells, but only in CPTH6-treated cells, most of the EGFP-LC3 puncta were not colocalized with LAMP-2, suggesting that fusion of autophagosomes with lysosomes was blocked. On the contrary, under starvation, EGFP-LC3 puncta and LAMP-2 colocalization was observed, as expected, demonstrating the correct fusion between autophagosomes and lysosomes.
We also tested whether CPTH6 treatment affected lysosomal function. In particular, the activity of the two lysosomal hydrolases (Figure 4b As shown by western blot analysis, using antibodies that recognize both immature and fully mature forms of cathepsin D and cathepsin B, an increased level of the premature form of cathepsin D was detected in U-937 cells after CPTH6 treatment, together with an increase in the heavy chain of the mature enzyme. In contrast, CPTH6 exposure did not cause any significant changes in the expression profile of cathepsin B (Figure 4b ). We next investigated CPTH6 effect on lysosomal permeability. As lysosomal permeability is accompanied by the release of cathepsins into cytosol where they may trigger cellular response, including autophagy, we measured enzymatic activity of acidic phosphatases in both whole-cell extracts and lysosomal fractions. As reported in Figure 4c , CPTH6 treatment did not affect lysosomal permeability activity being the acidic phosphatase similar in untreated and CPTH6-treated cells.
The effect of CPTH6 on autophagy is dependent on ATAT1 expression. We previously identified CPTH6 as a new inhibitor of histone acetyltransferase activity, and by testing its effect on a-tubulin, a decrease in acetylation level of the protein was observed in U-937 cells 14 and H1299 after 48 h of treatment; in contrast, CPTH6 treatment did not modulate the expression of HDAC6 deacetylase (Figure 5a) . To dissect the impact of tubulin acetylation status on CPTH6-induced modulation of autophagy, we silenced ATAT1 acetyltransferase and HDAC6 deacetylase expression using the siRNA approach. As shown in Figures 5b, d and e, HDAC6 expression silencing in H1299 cells determined an accumulation of acetylated tubulin, as expected, and concomitantly an induction of LC3B-II accumulation and its recruitment on autophagosome membranes. The same autophagic markers were increased by ATAT1 silencing that, as expected, induced a strong reduction of acetylated tubulin expression (Figures 5c-e) . Despite lacking HDAC6 expression, CPTH6 treatment elicited the same effect in terms of induction of LC3B-II accumulation (Figure 5b ) and enhancement of percentage of cells with EGFP-LC3B puncta (Figures 5d and e) . On the contrary, CPTH6 treatment failed to increase cells with EGFP-LC3B puncta and to accumulate LC3B-II proteins in cells in which the expression of ATAT1 was silenced (Figures 5c-e) . Thus, this indicates that the effect of CPTH6 on autophagy is dependent on ATAT1, but not HDAC6, expression.
We also assessed whether other compounds having high structural and activity similarities with CPTH6 could produce similar effects on the autophagic pathway. To this aim, U-937 cells were treated with CPTH derivatives CPTH2, CPTH9 and CPTH11 (Supplementary Figure 3A) , the three closely related compounds belonging to the same chemical class of CPTH6. 13 As reported in Figure 6a , treatment of cells with all CPTH derivatives determined an increase in LC3B-II and p62 proteins expression, even to a different extent. Notably, CPTH2 treatment also induced LC3B puncta in both H1299 (Figures 6b and c) and M14 cells (Supplementary Figure 3B,C) that, similar to CPTH6-treated cells, colocalize with p62 bodies (Figures 6d and e) .
The effect of CPTH6 on autophagic flux is dependent on the stimulus used to induce autophagy. Previous experiments demonstrated the effects of CPTH6 and its derivatives on basal autophagy. Thus, experiments were also performed to investigate the effect of CPTH6 on autophagy induced by different stimuli, such as serum starvation or RAD001, a second generation of mTOR pharmacological inhibitor. As reported in Figure 7a , H1299 cells exposed to serum starvation or CPTH6 showed an accumulation of LC3B-II Regarding the effect of CPTH6 on RAD001-induced autophagy, both RAD001 and CPTH6 resulted in an enhancement in the LC3B-II levels when compared with untreated cells, whereas, as previously observed (Figure 2f and Supplementary Figure 2A) , CPTH6 treatment induced p62 expression and, in combination with RAD001, resulted in a significant increase in the levels of the autophagosomal markers studied (Figure 7e) , indicating that the effect of CPTH6 on the autophagic flux was dependent on the stimulus used to induce autophagy.
Discussion
By using different approaches, we demonstrated that CPTH6 inhibits basal autophagy in several human tumor cell lines with To analyze which step of autophagosome biogenesis was affected by CPTH6, we used a genetic approach to silence the expression of several proteins acting at different steps of autophagy. Our data indicate that alteration of autophagy in CPTH6-treated cells involved a noncanonical molecular pathway that requires the classic Atg-7 conjugation machinery, but is independent of beclin-1. Beclin-1-p150-Vsp34 complex is considered a core component of the autophagy machinery that drives nucleation; nevertheless, beclin-independent mechanisms of autophagy induction have been demonstrated. 25, 26 It is conceivable that autophagosomal biogenesis bypasses the nucleation step, and that Atg proteins were recruited to the pre-existing membranes to drive the subsequent maturation of autophagosomes.
We also demonstrated that CPTH6-induced alterations in the autophagic pathway are LAMP-2 dependent, and LAMP-2 silencing was sufficient to cause the accumulation of LC3B-II and p62 proteins. This evidence is in accord with the notion that (1) LAMP-2 is essential for the proper fusion of lysosomes with autophagosomes, and hence for the removal of autophagosomes and (2) LC3B-II accumulation can be induced by chemical or genetic inhibition of the autophagosome maturation, such as LAMP-2 27 or rab7 siRNA. 28 Moreover, even though CPTH6 treatment induced the expression of cathepsin D, it did not affect the activity of acidic phosphatases and it did not impair lysosomal permeability activity.
The increased number of autophagosomes observed in response to CPTH6 is dependent on the balance between the rate of autophagosome generation and the rate of their conversion into autolysosomes. By inhibiting lysosomal acid hydrolases with bafilomicyn A1 or by preventing endosomal acidification with chloroquine, we determined that autophagosomes did not mature to autophagolysosomes under basal condition, even after short-time exposure to CPTH6, thus indicating that autophagy was blocked at a late stage.
In agreement with these results, p62 and NBR1, two polyubiquitin-binding proteins whose increase in the steadystate levels implies a block in the late stage of autophagy, are enhanced by CPTH6 treatment. 20, 24 Even though p62 protein degradation may happen via proteasomal pathway, 22 and a cross-talk between proteasome-mediated degradation and autophagy has been demonstrated, 21 we have evidence that CPTH6 did not act as a proteasome inhibitor.
Furthermore, inhibition of autophagic flux by CPTH6 is most likely a general function of CPTH derivatives and does not represent a cell type-specific phenomenon, as other three compounds with similar chemical structure caused the same inhibitory effect in several human tumor cell lines of different origins.
a-Tubulin has been identified as a major ATAT1/MEC-17 acetyltransferase 29 and HDAC6 deacetylase 30 substrate. The evidence that, in our experimental models, downregulation of both HDAC6 and ATAT1 increases markers of autophagy corroborates previous results demonstrating that regulation of acetylation/deacetylation balance of a-tubulin has important implications for autophagy. 31 As CPTH6 inhibits a-tubulin acetylation, our hypothesis is that CPTH6 could affect autophagosome maturation through its effect on a-tubulin acetylation. Tubulin hyperacetylation has been demonstrated to be necessary to allow kinesin-1-dependent JNK activation and stimulation of autophagosome formation, 32 and hence a possible effect of CPTH6 on this pathway can be hypothesized. Moreover, the evidence that CPTH6 treatment failed to increase cells with EGFP-LC3B puncta and to accumulate p62 and LC3B-II proteins in cells in which the expression of ATAT1 was silenced led us to speculate that ATAT1 could be another direct target of CPTH6; indeed, our previously published results identified CPTH6 as a novel pCAF and Gcn5 histone acetyltransferase inhibitor 14 and ATAT1 just belongs to the Gcn5 histone acetyltransferase family. 33 Nevertheless, we cannot exclude that CPTH6 may induce changing in tubulin acetylation status interfering with the activity of other acetyltransferases (like the Elongator complex ELP3 subunit) 34 and/or deacetylase such as SIRT2. 35 These data are in agreement with the evidence that defective autolysosome maturation after CPTH6 treatment was observed.
As, unlike what happens with tubulin, Atg proteins, including Atg-5, Atg-7 and Atg-8, need to be deacetylated to stimulate autophagy, in a way that involves p300 and SIRT1, 36, 37 we cannot exclude that CPTH6 could also act through an impairment of these proteins.
Our results also demonstrated that the effect of CPTH6 on autophagy was dependent on the stimulus used to induce autophagy. In fact, a different response of tumor cells, in terms of LC3B-II induction, was observed when the effect of CPTH6 was evaluated on nutrient-independent basal autophagy, or autophagy induced by serum starvation, or by pharmacological inducers such as RAD001. This difference can be related to different autophagic modalities previously demonstrated by different groups. For instance, HDAC6 has been demonstrated to control autophagosome maturation in basal autophagy condition, but to be completely dispensable for starvation-induced autophagy. 38 Similarly, kinesin-1 has been demonstrated to carry autophagosomes in basal condition, but it is not involved in motoring autophagosomes after nutrient deprivation. 32 Indeed, the decrease of autophagosome mobility associated with tubulin hyperacetylation induced by serum starvation 32 can be responsible for the different responses of cells to CPTH6 treatment in terms of enhancement of autophagic markers observed in the presence or absence of serum.
Taken together, our results expand our current knowledge about the bioactivity of CPTH6 and strongly suggest that CPTH6 acts on multiple targets in cancer cells and affects two different mechanisms: apoptosis and autophagy. Our previous paper demonstrated the ability of CPTH6 to activate the apoptotic program in several cancer cell lines.
14 In the present study we have demonstrated the ability of CPTH6 to prevent autophagy completion. The observation that either bcl-2 and bcl-xL overexpression or co-treatment with a pancaspase inhibitor did not prevent CPTH6-induced LC3B conversion (data not shown) strongly suggests that the effect of CPTH6 on autophagic flux is independent of the ability of the compound to induce apoptosis. 
Materials and Methods
Cell cultures and plasmids. Human AML (HL-60, U-937), melanoma (M14), lung (H1299, NCI-H460) and ovary (OVCA 433, SKOV-3) carcinoma cell lines were cultured in 10% inactivated fetal bovine serum (HyClone, Thermo Scientific, South Logan, UT, USA) in RPMI medium (Invitrogen, Carlsbad, CA, USA). For starvation, cells were incubated in RPMI medium without any supplement. Human ovary and lung carcinoma cell lines were purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). AML cell lines were a generous gift from Dr. Mauro Valtieri (Istituto Superiore di Sanità, Rome, Italy). Cells were stably transfected using Lipofectamine2000 (Invitrogen) according to the manufacturer's instructions. For EGFP-LC3B, mRFP-EGFP-LC3B (ptfLC3, plasmid 21074; Addgene, Cambridge, MA, USA), shBeclin-1 and sh-Control expressing cells, stable clones or mixed populations were cultured in the presence of geneticin (800 mg/ml, Sigma-Aldrich, St. Louis, MO, USA).
Pooled siRNA oligonucleotides (siGENOME SMART pool) against Atg-7, LAMP-2 and ATAT1 were purchased from Dharmacon RNA Technologies (Lafayette, CO, USA). For siRNA transfection, cells were seeded and transfected with 100 nM pooled oligonucleotide mixture by using Lipofectamine 2000 following the manufacturer's protocol. After transfection, media were removed and cells were allowed to recover in complete growth media for 48 h before using them for experiments. Gene silencing efficacy by various shRNAs or siRNAs was assessed by western blot assay.
Reagent preparation and treatments. CPTH6 and its analogs, cyclopentylidene-[4-(4 0 -chlorophenyl)thiazol-2-yl)hydrazone (CPTH2), 1-(4-(4-methoxyphenyl)thiazol-2-yl)-2-(2-methylcyclohexylidene)hydrazone (CPTH9) and 1-(4-(4-methoxyphenyl)thiazol-2-yl)-2-(3-methylcyclohexylidene)hydrazone (CPTH11), were synthesized and dissolved as previously reported. 13, 14 For all experiments, cells were treated with 1% DMSO as control. After 24 h from seeding, exponentially growing AML and solid tumor cells were treated with CPTH6 at concentrations ranging from 20 to 100 mM for 6-72 h. Bafilomicyn A1 (Baf A1, Santa Cruz Biotechnology, Santa Cruz, CA, USA) and 3-MA (Enzo Life Science, Plymouth Meeting, PA, USA), mTOR inhibitor RAD001 (GlaxoSmithKline, Brentford, Middlesex, UK) and proteasome inhibitor Z-leu-leu-leu-CHO (MG132, Santa Cruz Biotechnology) were dissolved in DMSO. Chloroquine diphosphate (CQ, Sigma-Aldrich) was dissolved in water.
Transmission electron microscopy. After treatment, cells were collected and centrifuged; the pellet was fixed with 2.5% glutaraldehyde in 0.1 M cacodylate buffer (pH 7.3) at room temperature for 20 min. After postfixation with 1% OsO 4 in 0.2 M cacodylate buffer (pH 7.3) at room temperature for 30 min, cells were dehydrated with ascending concentrations of ethanol, and embedded in epoxy resin (TAAB Laboratories Equipment Limited, Aldermarton, UK). Ultrathin sections, obtained with an LKB Ultratome Nova ultramicrotome (LKB, Bromma, Sweden), were stained with uranyl acetate and lead citrate and were examined with a Philips EM 208S electron microscope (FEICo, Eindhoven, The Netherlands).
Western blot analysis. After treatments, both detached and adherent cells were collected, lysed and total protein extracts were fractionated by SDS-PAGE, transferred to a nitrocellulose filter and subjected to immunoblot assay, as previously described.
14 Immunodetection was performed using antibodies directed to: p62, LAMP-2, HDAC6, NBR1, Ubiquitin (Santa Cruz Biotechnology), HSP72/73 (Calbiochem, San Diego, CA, USA), LC3B, acetyl-a-tubulin (K40; Sigma-Aldrich), cathepsin B, cathepsin D (Calbiochem), Atg-7 (Millipore, Billerica, MA, USA), phospho-Ik-Ba (ser32/ser36), total and phospho (ser473) AKT, total and phospho (ser2448) mTOR (Cell Signaling, Danvers, MA, USA) and HIF-1a (BD Pharmigen, San Diego, CA, USA). Anti-mouse or anti-rabbit immunoglobulin G (IgG)-horseradish peroxidase conjugated antibodies (Cell Signaling; Amersham Biosciences, Freiburg, Germany) were used as secondary antibodies in a 1 : 10 000 dilution. Antibody binding was visualized by enhanced chemiluminescence method (Amersham Biosciences) according to the manufacturer's specification and recorded on autoradiographic film (Amersham Biosciences).
Densitometric analysis. Developed films were acquired using GS-700 Imaging Densitometer (Bio-Rad Laboratories, Hercules, CA, USA) and processed with Corel Photo Paint 7.0 (Corel inc., Mountain View, CA, USA) to adjust image brightness and contrast. Densitometric evaluation was performed using Molecular Analyst Software (Bio-Rad) and normalized with relative controls depending on the analysis. In particular, LC3B-II and p62 protein levels versus housekeeping protein expression were analyzed and fold increase relative to control was presented.
Immunofluorescence microscopy. Cells grown on glass coverslips were fixed in 2% formaldehyde for 10 min at room temperature. Detection of autophagosomal structures was performed by fluorescence microscopy observing LC3B puncta in EGFP-LC3B-expressing cells. Autophagic flux was analyzed by fluorescence microscopy monitoring the distribution and alteration of mRFP-GFP-LC3B fluorescent signals. Colocalization experiments were performed using EGFP-LC3B M14-expressing cells stained with primary antibodies directed to p62 or LAMP-2 (Santa Cruz Biotechnology). Tetramethylrhodamine-5-(and 6)-isothiocyanate-conjugated Goat anti-mouse antibody (Jackson Lab, Bar Harbor, ME, USA) was used as a secondary antibody. Typically, at least 200 cells were counted, and cells with more than 10 puncta were considered autophagy positive.
For all fluorescence microscopy experiments, images were scanned under a Â 63 oil immersion objective and, to avoid bleed-through effects, each fluorescent signal was scanned independently using a Leica DMIRE2 microscope equipped with a Leica DFC 350FX camera, elaborated by a Leica FW4000 deconvolution software (Leica, Solms, Germany) and processed using Adobe PhotoShop software (Adobe Inc., Burlington, NJ, USA).
Lysosomal subfractionation and acid phosphatase assay. After treatments, cell homogenates from B3 Â 10 8 cells were enriched for lysosomal fraction by differential centrifugation followed by density centrifugation (Lysosome Extraction kit, Sigma-Aldrich). Acid phosphatase activity in homogenates was evaluated by Acid Phosphatase Assay kit (Sigma-Aldrich) according to the manufacturer's protocol.
Statistics. Experiments were replicated three times, unless otherwise indicated, and the data were expressed as means ± S.D. or mean ± S.E.M. Differences between groups were analyzed with a two-sided paired or unpaired t-test and they were considered to be statistically significant for Po0.05.
